logo

Slide Shows

Share
Events

Biotech Stocks Facing FDA Decision In September The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. This one-time gene therapy by the name Zynteglo, developed by bluebird bio Inc. (BLUE), reportedly carries a price tag of $2.8 million.

Biotech Stocks Facing FDA Decision In June 2022 As another month comes to a close, it’s time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what’s in store on the regulatory front in June.

Biotech Stocks Facing FDA Decision In March 2022 As another month comes to an end, it’s time to take a look back at some of the regulatory news that made headlines in February and look ahead to what the month of March has in store.

Biotech Stocks Facing FDA Decision In January 2022 As another month comes to an end, we take a look back at some of the regulatory news that dominated the headlines and look ahead to what’s in store for January.